Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anlotinib and TACE in middle-advanced hepatocellular carcinoma
NCT04066543Phase 2Unknown
- Sponsor
- Zhejiang Cancer Hospital
- Start
- Aug 2019
- Primary completion
- May 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of anlotinib in hepatocellular carcinoma (HCC) (2 arms), sponsored by Zhejiang Cancer Hospital. Primary endpoint: Progression-Free Survival at 12 months. Status: unknown.
02
Drugs
anlotinib
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT04066543.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04066543.